Discounted Cash Flow
Transmedics Group, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2018 | $14.7m | $-23.8m | $-26.4m | -162.1% | $-17.48 |
| 2019 | $25.8m (76.3%) | $-33.5m (-41.2%) | $-32.5m (-22.9%) | -129.8% (19.9%) | $-2.36 (86.5%) |
| 2020 | $25.6m (-0.8%) | $-28.7m (14.3%) | $-30.7m (5.3%) | -112.1% (13.6%) | $-1.16 (50.8%) |
| 2021 | $30.3m (18.0%) | $-44.2m (-53.8%) | $-32.4m (-5.4%) | -146.1% (-30.3%) | $-1.60 (-37.9%) |
| 2022 | $93.5m (208.8%) | $-36.2m (18.1%) | $-57.7m (-78.3%) | -38.8% (73.5%) | $-1.23 (23.1%) |
| 2023 | $241.6m (158.5%) | $-25.0m (30.9%) | $-164.9m (-185.6%) | -10.4% (73.3%) | $-0.77 (37.4%) |
| 2024 | $441.5m (82.7%) | $35.5m (241.7%) | $-80.9m (50.9%) | 8.0% (177.5%) | $1.07 (239.0%) |
| 2025 | $605.5m (37.1%) | $190.3m (436.6%) | $133.6m (265.0%) | 31.4% (291.3%) | $5.60 (423.4%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.